Home Featured Page 213

Featured

Latest

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program

HAVN Life Announces Departure of Rick Brar as Director

Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific &...

European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the...

MindMed CMO to Chair Digital Biomarkers Summit

Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial...

Psychedelic Bulletin: Small Pharma Secures Fast-Track Designation in UK; Boris Johnson...

More Evidence of the Chemical Compound Variability in Magic Mushrooms

PTSF82 – Wonderland Miami, with Patrick Moher of Microdose

Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy...

1...212213214...303 Page 213 of 303

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program

HAVN Life Announces Departure of Rick Brar as Director

Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific &...

European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the...

MindMed CMO to Chair Digital Biomarkers Summit

Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial...

Psychedelic Bulletin: Small Pharma Secures Fast-Track Designation in UK; Boris Johnson...

More Evidence of the Chemical Compound Variability in Magic Mushrooms

PTSF82 – Wonderland Miami, with Patrick Moher of Microdose

Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy...

EDITOR PICKS

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY